Literature DB >> 17242154

Lack of relationship between purine biosynthesis and vancomycin resistance in Staphylococcus aureus: a cautionary tale for microarray interpretation.

Paige M Fox1, Michael W Climo, Gordon L Archer.   

Abstract

Previous microarray data (E. Mongodin, J. Finan, M. W. Climo, A. Rosato, S. Gill, and G. L. Archer, J. Bacteriol. 185:4638-4643, 2003) noted an association in two vancomycin-intermediate Staphylococcus aureus (VISA) strains between high-level, passage-induced vancomycin resistance, a marked increase in the transcription of purine biosynthetic genes, and mutation of the putative purine regulator purR. Initial studies to report on the possible association between vancomycin resistance and alterations in purine metabolism in one of these strains (VP-32) confirmed, by Western analysis, an increase in the translation of PurH and PurM, two purine pathway enzymes. In addition, PurR was identified, by knockout and complementation in a vancomycin-susceptible strain, as a repressor of the purine biosynthetic operon in S. aureus, and the PurR missense mutation was shown to inactivate the repressor. However, despite the apparent relationship between increased purine biosynthesis and increased vancomycin resistance in VP-32, neither the addition of exogenous purines to a defined growth medium nor the truncation or inactivation of purR improved the growth of vancomycin-susceptible S. aureus in the presence of vancomycin. Furthermore, the passage of additional vancomycin-susceptible and VISA strains to high-level vancomycin resistance occurred without changes in cellular purine metabolism or mutation of purR despite the development of thickened cell walls in passaged strains. Thus, we could confirm neither a role for altered purine metabolism in the development of vancomycin resistance nor its requirement for the maintenance of a thickened cell wall. The failure of biochemical and physiological studies to support the association between transcription and phenotype initially found in careful microarray studies emphasizes the importance of follow-up investigations to confirm microarray observations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242154      PMCID: PMC1855472          DOI: 10.1128/AAC.01060-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

3.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

4.  Definition of the Bacillus subtilis PurR operator using genetic and bioinformatic tools and expansion of the PurR regulon with glyA, guaC, pbuG, xpt-pbuX, yqhZ-folD, and pbuO.

Authors:  H H Saxild; K Brunstedt; K I Nielsen; H Jarmer; P Nygaard
Journal:  J Bacteriol       Date:  2001-11       Impact factor: 3.490

5.  Altered production of penicillin-binding protein 2a can affect phenotypic expression of methicillin resistance in Staphylococcus aureus.

Authors:  C J Hackbarth; C Miick; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Cloning and characterization of a 12-gene cluster from Bacillus subtilis encoding nine enzymes for de novo purine nucleotide synthesis.

Authors:  D J Ebbole; H Zalkin
Journal:  J Biol Chem       Date:  1987-06-15       Impact factor: 5.157

7.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

8.  A transcriptional activator, homologous to the Bacillus subtilis PurR repressor, is required for expression of purine biosynthetic genes in Lactococcus lactis.

Authors:  M Kilstrup; J Martinussen
Journal:  J Bacteriol       Date:  1998-08       Impact factor: 3.490

9.  Dissemination among staphylococci of DNA sequences associated with methicillin resistance.

Authors:  G L Archer; D M Niemeyer; J A Thanassi; M J Pucci
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  2003-12       Impact factor: 3.490

View more
  9 in total

1.  Impact of Exposure of Methicillin-Resistant Staphylococcus aureus to Polyhexanide In Vitro and In Vivo.

Authors:  A Renzoni; E Von Dach; C Landelle; S M Diene; C Manzano; R Gonzales; W Abdelhady; C P Randall; E J Bonetti; D Baud; A J O'Neill; A Bayer; A Cherkaoui; J Schrenzel; S Harbarth; P François
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Transcriptome and functional analysis of the eukaryotic-type serine/threonine kinase PknB in Staphylococcus aureus.

Authors:  Stefanie Donat; Karin Streker; Tanja Schirmeister; Sonja Rakette; Thilo Stehle; Manuel Liebeke; Michael Lalk; Knut Ohlsen
Journal:  J Bacteriol       Date:  2009-04-17       Impact factor: 3.490

Review 3.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

4.  De Novo Resistance to Arg10-Teixobactin Occurs Slowly and Is Costly.

Authors:  Daniel G Lloyd; Benjamin J Schofield; Matthew R Goddard; Edward J Taylor
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

5.  Gene acquisition at the insertion site for SCCmec, the genomic island conferring methicillin resistance in Staphylococcus aureus.

Authors:  Michael J Noto; Barry N Kreiswirth; Alastair B Monk; Gordon L Archer
Journal:  J Bacteriol       Date:  2007-12-14       Impact factor: 3.490

6.  Insights Into the Impact of Small RNA SprC on the Metabolism and Virulence of Staphylococcus aureus.

Authors:  Jingwen Zhou; Huanqiang Zhao; Han Yang; Chunyan He; Wen Shu; Zelin Cui; Qingzhong Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-02-23       Impact factor: 5.293

7.  Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  Benjamin P Howden; Danielle J Smith; Ashley Mansell; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  BMC Microbiol       Date:  2008-02-27       Impact factor: 3.605

8.  Living with an imperfect cell wall: compensation of femAB inactivation in Staphylococcus aureus.

Authors:  Judith Hübscher; Andrea Jansen; Oliver Kotte; Juliane Schäfer; Paul A Majcherczyk; Llinos G Harris; Gabriele Bierbaum; Matthias Heinemann; Brigitte Berger-Bächi
Journal:  BMC Genomics       Date:  2007-09-04       Impact factor: 3.969

9.  Apt (Adenine Phosphoribosyltransferase) Mutation in Laboratory-Selected Vancomycin-Intermediate Staphylococcus aureus.

Authors:  Reena Lamichhane-Khadka; Santosh Dulal; Jesus A Cuaron; Richard Pfeltz; Sushim Kumar Gupta; Brian J Wilkinson; John E Gustafson
Journal:  Antibiotics (Basel)       Date:  2021-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.